Novel, non-nitrocatechol catechol-O-methyltransferase inhibitors modulate dopamine neurotransmission in the frontal cortex and improve cognitive flexibility

RATIONALE: Cognitive impairment is a primary feature of many neuropsychiatric disorders and there is a need for new therapeutic options. Catechol-O-methyltransferase (COMT) inhibitors modulate cortical dopaminergic function and have been proposed as potential cognitive enhancers. Unfortunately, curr...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Psychopharmacology (Berl)
Auteurs principaux: Byers, Spencer, Buchler, Ingrid P., DePasquale, Michael, Rowley, Helen L., Kulkarni, Rajiv S., Pinder, Lucy, Kolobova, Anna, Li, Cailian, Au, Vinh, Akuma, Daniel, Zhang, Gongliang, Wei, Huijun, Cheetham, Sharon C., Barrow, James C., Carr, Gregory V.
Format: Artigo
Langue:Inglês
Publié: 2020
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7790123/
https://ncbi.nlm.nih.gov/pubmed/32474681
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00213-020-05566-0
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires